カスタム組換えタンパク質の世界市場

カスタム組換えタンパク質の世界市場は2030年までに100億米ドルに達する見込み

2024年に53億米ドルと推定されるカスタム組換えタンパク質の世界市場は、2024年から2030年にかけてCAGR 11.2%で成長し、2030年には100億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである哺乳類発現システムは、CAGR 12.8%を記録し、分析期間終了までに44億米ドルに達すると予想されます。細菌発現システムセグメントの成長率は、分析期間中CAGR 8.4％と推定されます。

米国市場は14億米ドルと推定、中国はCAGR 15.5％で成長すると予測

米国のカスタム組換えタンパク質市場は2024年に14億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに21億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは15.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.0％と10.1％と予測されています。欧州では、ドイツがCAGR 8.9%で成長すると予測されています。

世界のカスタム組換えタンパク質市場- 主要動向と促進要因のまとめ

カスタム組換えタンパク質が生物医学研究および治療開発に不可欠となる理由とは？

カスタム組換えタンパク質は、その比類のない特異性、一貫性、実験デザインにおける柔軟性により、ますます現代の生物医学研究と医薬品開発の基幹となりつつあります。生体組織から抽出されたネイティブなタンパク質とは異なり、組換えタンパク質は、高純度かつ高収率で標的タンパク質を発現するように設計された遺伝子操作生物（最も一般的なのは、細菌、酵母、昆虫、哺乳類細胞）を介して生産されます。この方法によって、科学者はタンパク質の配列をカスタマイズしたり、タグを追加したり、変異を導入したりすることができ、タンパク質の機能、受容体相互作用、酵素機構の研究に不可欠なレベルのカスタマイズが可能になります。創薬においては、カスタムタンパク質は抗体開発における抗原、ハイスループットスクリーニングのターゲット、結晶学やクライオ電子顕微鏡における構造モデルとしての役割を果たします。その安定した品質と再現性により、精度が要求される診断キット製造やワクチン製剤に最適です。さらに、二重特異性抗体、融合タンパク質、人工酵素など、バイオ治療薬の複雑化に伴い、正確な構造的・機能的基準を満たすカスタムタンパク質の作製が必要とされています。プロテオミクスと精密医療の普及は、疾患バイオマーカーや個人の遺伝子プロファイルに合わせた、特異性の高いタンパク質ツールの必要性をさらに強調しています。その結果、カスタム組換えタンパク質はもはや単なる試薬ではなく、ライフサイエンス、診断、バイオ医薬品パイプライン全体のイノベーションを実現する中心的な存在として捉えられています。

技術革新は、カスタム組換えタンパク質の設計、製造、精製をどのように強化しているのでしょうか？

カスタム組換えタンパク質市場は、タンパク質発現、エンジニアリング、精製のスピード、精度、スケーラビリティを劇的に向上させた技術的進歩により、再構築されています。最もインパクトのある開発の一つは、CRISPRやその他のゲノム編集ツールを用いて宿主細胞株を最適化し、より効率的な遺伝子統合と発現を可能にしたことです。発現系自体も多様化しており、複雑な翻訳後修飾には哺乳類細胞が有利である一方、迅速かつコスト効率の高いタンパク質生産には細菌および酵母系が不可欠であることに変わりはないです。先進的なベクターとプロモーターは、現在、厳密な発現制御と高い収率を可能にし、研究用・治療用タンパク質の市場投入までの時間を短縮しています。コドンの最適化、シグナルペプチドの設計、折りたたみシャペロンにおける革新は、タンパク質の溶解性と機能性を向上させました。精製面では、アフィニティークロマトグラフィー、自動液体処理システム、高分解能質量分析計により、発現が困難なタンパク質であっても、高い純度レベルと構造的完全性が確保されています。さらに、AIを駆使したタンパク質設計プラットフォームが安定性、免疫原性、活性の予測に使われるようになり、合成が始まる前からタンパク質の変異体をよりインテリジェントに設計できるようになっています。企業はまた、研究者が遺伝子配列を提出し、わずか数週間で精製されたカスタムタンパク質を受け取ることを可能にする、エンドツーエンドの自動化とクラウドベースのプラットフォームに投資しています。このような技術的改善により、生物学的発見と治療法の革新のペースが加速され、カスタム組換えタンパク質サービスの信頼性、利用しやすさ、不可欠性が高まっています。

カスタム組換えタンパク質の需要増加を牽引している業界および調査動向は？

カスタム組換えタンパク質の需要は、製薬開発、診断、農業、学術科学にまたがる多くの産業および研究動向によって推進されています。製薬分野では、生物製剤やバイオシミラーの台頭により、細胞ベースのアッセイや毒性試験、製剤開発に使用するカスタマイズされたタンパク質のニーズが劇的に高まっています。免疫療法や標的療法が台頭するにつれ、製薬会社は既製品よりも正確にヒトの生理機能を模倣したカスタムメイドのサイトカイン、成長因子、チェックポイントタンパク質を求めるようになっています。診断学では、精密医療の推進により、イムノアッセイやELISAで特異的バイオマーカーや検出ターゲットとなる組換えタンパク質の創製が進んでいます。研究機関も構造的・機能的プロテオミクスへの投資を増やしており、部位特異的修飾、蛍光タグ、変異パネルを持つ人工タンパク質への需要を促進しています。農業バイオテクノロジーも新興市場の一つであり、カスタムタンパク質は植物免疫の研究、耐病性作物の開発、酵素ベースの肥料の開発に使用されています。教育研究所やCROは、納期を短縮し、実験の厳密性を維持するために組換えタンパク質サービスを採用しています。さらに、COVID-19パンデミックは、迅速なワクチン開発、抗体検査、治療スクリーニングにおける組換えタンパク質の重要性にスポットライトを当て、その世界の知名度と認知価値を加速させました。このような広範な用途は、既存の科学分野と新興の科学分野の両方において、発見、革新、製品開発を促進する上でカスタムタンパク質の重要性を強調しています。

世界のカスタム組換えタンパク質市場の成長を促進する主な要因は？

世界のカスタム組換えタンパク質市場は、R&D投資の増加、慢性疾患や遺伝性疾患の有病率の増加、個別化医療へのシフトの加速などの要因が重なり、力強い成長を遂げています。主要な促進要因は、バイオ医薬品パイプラインの拡大であり、そこでは、早期発見から臨床検証までのあらゆる段階でオーダーメイドのタンパク質が必要とされます。モノクローナル抗体、ワクチン、遺伝子治療を含む生物製剤の世界の急増は、有効性試験と規制遵守のためにカスタマイズされたタンパク質の安定供給を必要としています。さらに、ライフサイエンス研究に対する政府および民間部門の資金は、特にゲノム研究、腫瘍研究、感染症研究において歴史的な水準に達しており、タンパク質カスタマイズサービスのための肥沃な土壌を作り出しています。ユニークなタンパク質コンストラクトへの迅速で信頼性の高いアクセスを求める産学連携やCRO（医薬品開発業務受託機関）の増加により、顧客基盤はさらに拡大しています。新興国もバイオテクノロジーの能力を高めており、ローカライズされたカスタマイズ可能なタンパク質生産サービスへの需要を高めています。FDAやEMAのような規制機関は現在、生物製剤の厳格なバリデーションを重視しており、高品質でトレーサブルなタンパク質試薬の必要性が高まっています。既製品では調達できない複雑なマルチドメインや融合タンパク質を追求する研究者が増えるにつれ、オーダーメイドの組み換えソリューションの魅力は高まり続けています。技術的な拡張性や納期の改善と相まって、これらの市場促進要因は世界のカスタム組換えタンパク質市場の長期的な存続と成長を確実なものにしています。

セグメント

発現系（哺乳類、細菌、昆虫、酵母、その他の発現系）;エンドユーザー（研究機関、製薬・バイオテクノロジー企業、契約研究機関、その他のエンドユーザー）

調査対象企業の例（全39件）

• Abcam plc
• Abnova Corporation
• ACROBiosystems
• Aviva Systems Biology
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• BPS Bioscience, Inc.
• CER Groupe
• Creative BioMart
• Enzo Biochem Inc.
• Eurogentec
• GenScript Biotech Corporation
• Merck KGaA
• Miltenyi Biotec
• Novoprotein Scientific Inc.
• ProSpec-Tany TechnoGene Ltd.
• Proteintech Group, Inc.
• RD-Biotech
• Sino Biological Inc.
• Thermo Fisher Scientific Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Custom Recombinant Proteins Market to Reach US$10.0 Billion by 2030

The global market for Custom Recombinant Proteins estimated at US$5.3 Billion in the year 2024, is expected to reach US$10.0 Billion by 2030, growing at a CAGR of 11.2% over the analysis period 2024-2030. Mammalian Expression System, one of the segments analyzed in the report, is expected to record a 12.8% CAGR and reach US$4.4 Billion by the end of the analysis period. Growth in the Bacteria Expression System segment is estimated at 8.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 15.5% CAGR

The Custom Recombinant Proteins market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 15.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.0% and 10.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.9% CAGR.

Global Custom Recombinant Proteins Market - Key Trends & Drivers Summarized

Why Are Custom Recombinant Proteins Becoming Essential in Biomedical Research and Therapeutic Development?

Custom recombinant proteins are increasingly becoming the backbone of modern biomedical research and drug development due to their unparalleled specificity, consistency, and flexibility in experimental design. Unlike native proteins extracted from biological tissues, recombinant proteins are produced via genetically engineered organisms-most commonly bacteria, yeast, insect, or mammalian cells-designed to express target proteins in high purity and yield. This method allows scientists to tailor protein sequences, add tags, or introduce mutations, offering a level of customization that is vital for studying protein function, receptor interactions, and enzyme mechanisms. In drug discovery, custom proteins serve as antigens in antibody development, targets for high-throughput screening, and structural models in crystallography and cryo-electron microscopy. Their consistent quality and reproducibility make them ideal for diagnostic kit manufacturing and vaccine formulation, where precision is non-negotiable. Moreover, the growing complexity of biotherapeutics-such as bispecific antibodies, fusion proteins, and engineered enzymes-has necessitated the creation of custom proteins that meet exact structural and functional criteria. The increasing adoption of proteomics and precision medicine further underscores the need for highly specific protein tools tailored to disease biomarkers or individual genetic profiles. As a result, custom recombinant proteins are no longer viewed as mere reagents but as central enablers of innovation across life sciences, diagnostics, and biopharmaceutical pipelines.

How Are Technological Innovations Enhancing the Design, Production, and Purification of Custom Recombinant Proteins?

The custom recombinant proteins market is being reshaped by technological advancements that have dramatically improved the speed, accuracy, and scalability of protein expression, engineering, and purification. One of the most impactful developments is the use of CRISPR and other genome editing tools to optimize host cell lines, enabling more efficient gene integration and expression. Expression systems themselves have diversified, with mammalian cells favored for complex post-translational modifications, while bacterial and yeast systems remain essential for rapid and cost-effective protein production. Advanced vectors and promoters now allow for tightly regulated expression and higher yields, reducing time to market for research and therapeutic proteins. Innovations in codon optimization, signal peptide design, and folding chaperones have enhanced protein solubility and functionality. On the purification front, affinity chromatography, automated liquid handling systems, and high-resolution mass spectrometry are ensuring high purity levels and structural integrity, even in difficult-to-express proteins. Moreover, AI-driven protein design platforms are now being used to predict stability, immunogenicity, and activity, allowing for more intelligent engineering of protein variants before synthesis even begins. Companies are also investing in end-to-end automation and cloud-based platforms that allow researchers to submit gene sequences and receive purified custom proteins in just weeks. These technological improvements are accelerating the pace of biological discovery and therapeutic innovation, making custom recombinant protein services more reliable, accessible, and indispensable.

What Industry and Research Trends Are Driving the Increasing Demand for Custom Recombinant Proteins?

The demand for custom recombinant proteins is being propelled by a host of industry and research trends that span pharmaceutical development, diagnostics, agriculture, and academic science. In the pharmaceutical sector, the rise of biologics and biosimilars has dramatically increased the need for customized proteins for use in cell-based assays, toxicity testing, and formulation development. As immunotherapy and targeted therapies gain ground, pharmaceutical companies are requesting custom cytokines, growth factors, and checkpoint proteins that mimic human physiology more accurately than off-the-shelf alternatives. In diagnostics, the push for precision medicine has led to the creation of recombinant proteins that serve as specific biomarkers or detection targets in immunoassays and ELISAs. Research institutions are also investing more in structural and functional proteomics, driving demand for engineered proteins with site-specific modifications, fluorescent tags, or mutation panels. Agricultural biotechnology is another emerging market, where custom proteins are used to study plant immunity, develop disease-resistant crops, and engineer enzyme-based fertilizers. Educational labs and CROs are adopting recombinant protein services to reduce turnaround times and maintain experimental rigor. Furthermore, the COVID-19 pandemic spotlighted the importance of recombinant proteins in rapid vaccine development, antibody testing, and therapeutic screening-accelerating their global visibility and perceived value. These broad-based applications underscore the centrality of custom proteins in fueling discovery, innovation, and product development across both established and emerging scientific fields.

What Are the Key Drivers Fueling Growth in the Global Custom Recombinant Proteins Market?

The global custom recombinant proteins market is experiencing robust growth driven by converging forces such as rising R&D investments, increasing prevalence of chronic and genetic diseases, and the accelerating shift toward personalized medicine. A primary growth driver is the expansion of biopharmaceutical pipelines, where tailored proteins are required for every stage from early discovery to clinical validation. The global surge in biologics-including monoclonal antibodies, vaccines, and gene therapies-necessitates the consistent supply of customized proteins for efficacy testing and regulatory compliance. Additionally, government and private sector funding for life sciences research has reached historic levels, particularly in genomics, oncology, and infectious disease studies, creating a fertile ground for protein customization services. The growing number of academic-industry collaborations and contract research organizations (CROs) seeking quick, reliable access to unique protein constructs further expands the customer base. Emerging economies are also ramping up their biotechnology capabilities, increasing demand for localized, customizable protein production services. Regulatory agencies like the FDA and EMA now emphasize rigorous validation of biologics, increasing the need for high-quality, traceable protein reagents. As more researchers pursue complex, multi-domain, and fusion proteins that cannot be sourced off-the-shelf, the appeal of bespoke recombinant solutions continues to rise. Coupled with technological scalability and improvements in delivery timelines, these drivers are ensuring the long-term viability and growth of the global custom recombinant proteins market.

SCOPE OF STUDY:

The report analyzes the Custom Recombinant Proteins market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Expression System (Mammalian, Bacteria, Insect, Yeast, Other Expression Systems); End-User (Research Institutes, Pharma & Biotech Companies, Contract Research Organizations, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

• Abcam plc
• Abnova Corporation
• ACROBiosystems
• Aviva Systems Biology
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• BPS Bioscience, Inc.
• CER Groupe
• Creative BioMart
• Enzo Biochem Inc.
• Eurogentec
• GenScript Biotech Corporation
• Merck KGaA
• Miltenyi Biotec
• Novoprotein Scientific Inc.
• ProSpec-Tany TechnoGene Ltd.
• Proteintech Group, Inc.
• RD-Biotech
• Sino Biological Inc.
• Thermo Fisher Scientific Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Custom Recombinant Proteins - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Growth in Precision Medicine and Targeted Therapy Throws the Spotlight on Custom Recombinant Protein Services
  • Expansion of Biopharmaceutical R&D Pipelines Drives Demand for Protein Expression in Mammalian and E. coli Systems
  • Increased Complexity of Drug Targets Strengthens the Business Case for Tailored, High-Purity Recombinant Proteins
  • Rise in Vaccine Development and Antibody Engineering Fuels Demand for Custom Antigen and Enzyme Production
  • Push Toward Synthetic Biology Applications Accelerates Adoption of Modular Protein Design Services
  • Integration in Cell and Gene Therapy Workflows Propels Growth of GMP-Grade Custom Protein Manufacturing
  • Rising Need for Quality Controls in Diagnostics Sustains Use of Labeled and Modified Custom Proteins
  • Increased Interest in Epitope Mapping and Biomarker Discovery Drives Growth in Proteomics-Oriented Custom Services
  • Expansion of Protein Arrays and Assay Development Throws the Spotlight on Batch-to-Batch Reproducibility
  • Advancements in Expression Optimization Tools Strengthen Yield and Activity of Difficult-to-Express Proteins
  • Emerging Demand for Plant-Based and Insect Cell Systems Diversifies the Expression System Landscape
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Custom Recombinant Proteins Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Custom Recombinant Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Custom Recombinant Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Mammalian by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Mammalian by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Mammalian by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Bacteria by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Bacteria by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Bacteria by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Insect by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Insect by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Insect by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Yeast by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Yeast by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Yeast by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Expression Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Expression Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Expression Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Custom Recombinant Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: Canada 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• JAPAN
  • Custom Recombinant Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Japan 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• CHINA
  • Custom Recombinant Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 50: China Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: China Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: China 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 53: China Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: China 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• EUROPE
  • Custom Recombinant Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Custom Recombinant Proteins by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Europe 15-Year Perspective for Custom Recombinant Proteins by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Europe 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Europe 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• FRANCE
  • Custom Recombinant Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 65: France Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: France Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: France 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 68: France Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: France Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: France 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• GERMANY
  • Custom Recombinant Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 71: Germany Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Germany Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Germany 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 74: Germany Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Germany Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Germany 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 77: Italy Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Italy Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Italy 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 80: Italy Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Italy Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Italy 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Custom Recombinant Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 83: UK Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: UK Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: UK 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 86: UK Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: UK Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: UK 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 89: Spain Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Spain Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Spain 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 92: Spain Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Spain Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Spain 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 95: Russia Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Russia Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Russia 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 98: Russia Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Russia Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Russia 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Rest of Europe Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Rest of Europe 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Rest of Europe Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Rest of Europe 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Custom Recombinant Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Custom Recombinant Proteins by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Asia-Pacific 15-Year Perspective for Custom Recombinant Proteins by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Asia-Pacific 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Asia-Pacific Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Asia-Pacific 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Custom Recombinant Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 116: Australia Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Australia Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Australia 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 119: Australia Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Australia Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Australia 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• INDIA
  • Custom Recombinant Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 122: India Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: India Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: India 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 125: India Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: India Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: India 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 128: South Korea Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: South Korea Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: South Korea 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 131: South Korea Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: South Korea Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: South Korea 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Asia-Pacific Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Asia-Pacific Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Custom Recombinant Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Custom Recombinant Proteins by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Latin America 15-Year Perspective for Custom Recombinant Proteins by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 143: Latin America Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Latin America Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Latin America 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 146: Latin America Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Latin America Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Latin America 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 149: Argentina Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Argentina Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Argentina 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 152: Argentina Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Argentina Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Argentina 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 155: Brazil Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Brazil Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Brazil 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 158: Brazil Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Brazil Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Brazil 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 161: Mexico Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Mexico Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Mexico 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 164: Mexico Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Mexico Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Mexico 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Rest of Latin America Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Rest of Latin America 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Rest of Latin America Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Rest of Latin America 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Custom Recombinant Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Custom Recombinant Proteins by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Middle East 15-Year Perspective for Custom Recombinant Proteins by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 176: Middle East Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Middle East Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Middle East 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 179: Middle East Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Middle East Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Middle East 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 182: Iran Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Iran Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Iran 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 185: Iran Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Iran Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Iran 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 188: Israel Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Israel Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Israel 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 191: Israel Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Israel Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Israel 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Saudi Arabia Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Saudi Arabia 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Saudi Arabia Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Saudi Arabia 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 200: UAE Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: UAE Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: UAE 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 203: UAE Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: UAE Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: UAE 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Middle East Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Rest of Middle East 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Rest of Middle East Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Rest of Middle East 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
• AFRICA
  • Custom Recombinant Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 212: Africa Recent Past, Current & Future Analysis for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Africa Historic Review for Custom Recombinant Proteins by Expression System - Mammalian, Bacteria, Insect, Yeast and Other Expression Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Africa 15-Year Perspective for Custom Recombinant Proteins by Expression System - Percentage Breakdown of Value Sales for Mammalian, Bacteria, Insect, Yeast and Other Expression Systems for the Years 2015, 2025 & 2030
  • TABLE 215: Africa Recent Past, Current & Future Analysis for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Africa Historic Review for Custom Recombinant Proteins by End-user - Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Africa 15-Year Perspective for Custom Recombinant Proteins by End-user - Percentage Breakdown of Value Sales for Research Institutes, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030

IV. COMPETITION